Stability indicating high performance liquid chromatographic assay for the pharmacokinetics of cyclooxygenase (COX-2) inhibitor etoricoxib in rats

African Journal of Pharmacy and Pharmacology

Volumn 3, Issue 7, 2009, Pages 339-346

  Radwan, Mahasen A ^a   Zaghloul, Iman Y ^a   Abd Elbaky, Nayira A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

COX 2; Etoricoxib; Flurbiprofen; HPLC; Pharmacokinetics; Rats

Indexed keywords

ACICLOVIR; AMLODIPINE; DICLOFENAC; ETORICOXIB; FLUCONAZOLE; FLURBIPROFEN; INDIUM 111; INDOMETACIN; KETAMINE; KETOCONAZOLE; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NAPROXEN; PARACETAMOL; PIPERACILLIN; PIROXICAM; TRAMADOL; VORICONAZOLE; WARFARIN;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; REPRODUCIBILITY; VALIDATION PROCESS;

EID: 77953672356     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abrahim A, Hartman R, Ge Z, Mao B, Marcoux J, (2002). Development of a derivatization method, coupled with reverse phase HPLC, for monitoring the formation of an enolate intermediate J. Liq. Chromatogr. Rel. Technol. 25: 1049-1062.
2. Agrawal NG, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, Neu DC, Gottesdiener KM, (2001). Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J. Clin. Pharmacol. 41: 1106-1110
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, (2000). Comparison of upper gastrointestinal toxicityof rofecoxib and naproxen in patients with rheumatoid arthritis.
4. VIGOR study group N. Engl. J. Med. 343: 1520-1528, 1522 p following 1528.
5. Brautigam L, Nefflen JU, Geisslinger G (2003). Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. J. Chromatogr. B 788: 309-315. (Pubitemid 36428534)
6. Chan CC, Boyce S, Brideau C, Charleson W, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Mahasen et al. 345 Prasit P, Rodger I (1999). Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Pharmacol. Exp. Ther. 290: 551-560
7. Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA, (2001). In Vitro Metabolism Considerations, Including Activity Testing of Metabolites, in the Discovery and Selection of the COX-2 Inhibitor Etoricoxib (MK- 0663) Bioorg. Med. Chem. Lett.11(2001): 1059-1062.
8. Cochrane DJ, Jarvis B, Keating GM, (2002). Etoricoxib. Drugs. 62: 2637-2651
9. Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K, (2003). Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. 43 :573-585
10. FDA Arthritis Advisory Committee. Briefing information NDA 20- 998/S009 Celebrex (celecoxib). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm (accessed Jan 18, 2007).
11. Friesen RW, Brideau C, Chan CC, Charleson S, Deschenes D, Dube D, Etheir D, Fortin R, Gauthier JY, Girard Y, Gorden R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong Z, Visco D, Xu LJ, Young RN, (1998). 2-Pyridinyl-3-(4- methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 19: 2777-2782
12. Gibaldi M and Perrier D, Pharmacokinetics, 2nd Ed., Marcel Dekker, New York (1982).
13. Hartmann R, Abrahim A, Clausen A, Mao B, Crocker LS, Ge Z (2003). Development and Validation of an HPLC Method for the Impurity and Quantitative Analysis of Etoricoxib. J. Liq. Chromatogr. Rel. Technol. 26: 2551-2566.
14. Hawley C, (1999). COX-2 inhibitors. Lancet 353: 307.
15. Matthews CZ, Woolf EJ, Lin L, Fang W, Hsieh J, Ha S, Simpson R, Matuszewski BK, (2001). High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J. Chromatogr. B 751: 237-246 (Pubitemid 32126311)
16. Patrignani P, Capone ML, Tacconelli S (2003). Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin. Pharmacother. 4: 265-284
17. Pavan Kumar VV, Vinu MC, Ramani AV, Mullangi R, Srinivas NR (2006). Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by highperformance liquid chromatography with UV detection. Biomed. Chromatogr. 20: 125-132
18. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rodgers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhanng YY, Isakson PC, (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40: 1347-1365 (Pubitemid 27198082)
19. Prasit P, Wang Z, Brideau C, Chan C C, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, (1999). The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)- furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg. Med. Chem. Lett. 9: 1773-1778
20. Ramakrishna NVS, Vishwottam KN, Wishu S, Koteshwara M, (2005). Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction. J. Chromatogr. B, 816: 215-221.
21. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS (1995). Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55: 1464-1472.
22. Reddy BS, Rao CV, Seibert K, (1996). Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56: 4566-4569. (Pubitemid 26338047)
23. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Etheir D, Falgueyret JP, Friesen RW, Girard Y, Gorden R, Greig GM, Guay J, Mancini J, Ouellet M, Wong E, Visco D, Xu LJ, Boyce S, Girard Y, Prasit P, Zamboni R, Gresser M, Ford AW, Young HRN, Chan CC, (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharm. Exp. Ther. 296: 558-566
24. Rose MJ, Agrawal N, Woolf EJ, Matuszewski BK, (2002). Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS. J. Pharm. Sci. 91: 405-412.
25. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group. (2004). Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665-674 (Pubitemid 39140622)
26. Simmons DL, Botting RM, Hla T, (2004). Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 56: 387-437.
27. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators. (2006). Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESSI Study. Am J. Med. 119: 255-266
28. Stichtenoth DO, Frolich JC, (2003). The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs. 63:33-45.
29. Werner U, Werner D, Hinz B, Lambrecht C, Brune K (2005). A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. Biomed Chromatogr. 19: 113-118. (Pubitemid 40425694)